Literature DB >> 8408015

The dihydrofolate reductase domain of Plasmodium falciparum thymidylate synthase-dihydrofolate reductase. Gene synthesis, expression, and anti-folate-resistant mutants.

W Sirawaraporn1, P Prapunwattana, R Sirawaraporn, Y Yuthavong, D V Santi.   

Abstract

A 693-base pair gene coding for the 27,132-dalton dihydrofolate reductase (DHFR) domain of the thymidylate synthase-dihydrofolate reductase (TS-DHFR) bifunctional protein of Plasmodium falciparum was designed to have Escherichia coli codon preference and multiple unique restriction sites and was chemically synthesized. The gene was overexpressed (> 50% total cellular protein) in E. coli as insoluble inclusion bodies which could be unfolded and refolded to recover soluble enzyme activity. The refolded DHFR was purified by methotrexate-Sepharose affinity chromatography to give the homogeneous enzyme. Active site titration with methotrexate revealed that the purified protein was fully active. The purified DHFR migrates as a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with apparent mass of approximately 30 kDa, and gel filtration showed that the protein is a monomer. The yield of purified enzyme was about 5-6 mg/liter of bacterial culture. Kinetic properties of the purified recombinant DHFR were similar to those reported for wild type bifunctional TS-DHFR. Cassette mutagenesis of the synthetic gene was performed to give the S108N and the N51I + S108N mutants which provided DHFRs analogous to pyrimethamine-resistant mutants found in nature.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408015

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Essential protein-protein interactions between Plasmodium falciparum thymidylate synthase and dihydrofolate reductase domains.

Authors:  S Shallom; K Zhang; L Jiang; P K Rathod
Journal:  J Biol Chem       Date:  1999-12-31       Impact factor: 5.157

2.  Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya.

Authors:  Abigael Mbaisi; Pamela Liyala; Fredrick Eyase; Rachel Achilla; Hosea Akala; Julia Wangui; Josphat Mwangi; Finnley Osuna; Uzma Alam; Bonnie L Smoak; Jon M Davis; Dennis E Kyle; Rodney L Coldren; Carl Mason; Norman C Waters
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  Malaria antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) polymorphisms in humans and Anopheles mosquitoes.

Authors:  Sungano Mharakurwa; Taida Kumwenda; Mtawa A P Mkulama; Mulenga Musapa; Sandra Chishimba; Clive J Shiff; David J Sullivan; Philip E Thuma; Kun Liu; Peter Agre
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 4.  Status of antimalarial drugs under development.

Authors:  P L Olliaro; P I Trigg
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

5.  Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites.

Authors:  L K Basco; R Tahar; P Ringwald
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

6.  Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase.

Authors:  W Sirawaraporn; T Sathitkul; R Sirawaraporn; Y Yuthavong; D V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 7.  Pyrimidine metabolism in schistosomes: A comparison with other parasites and the search for potential chemotherapeutic targets.

Authors:  Mahmoud H El Kouni
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2017-07-21       Impact factor: 2.231

8.  Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates.

Authors:  M Imwong; S Pukrittakayamee; S Looareesuwan; G Pasvol; J Poirreiz; N J White; G Snounou
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.

Authors:  Deanpen Japrung; Ubolsree Leartsakulpanich; Sudsanguan Chusacultanachai; Yongyuth Yuthavong
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  Computational analysis of binding between malarial dihydrofolate reductases and anti-folates.

Authors:  Kiattawee Choowongkomon; Sasikrit Theppabutr; Napat Songtawee; Nicholas P J Day; Nicholas J White; Charles J Woodrow; Mallika Imwong
Journal:  Malar J       Date:  2010-03-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.